The Brand Name RANEX Has Generic Salt :: RANOLAZINE 

RANEX  Is From Company Cadila Hc. Priced :: Rs. 68

RANEX have RANOLAZINE is comes under Sub class Anti Anginals of  Main Class Cardiovascular System

Main Medicine Class:: Cardiovascular System  Sub Medicine Class :: Anti Anginals 

Indications for Drugs ::

Chronic angina

Drug Dose ::

Initiate Ranolazine dosing at 500 mg twice daily and increase to 1000 mg twice daily, if needed, based on clinical symptoms. The maximum recommended daily dose of Ranolazine is 1000 mg twice daily. If a dose of Ranolazine is missed, take the prescribed dose at the next scheduled time; do not double the next dose.

Contraindication ::

Taking strong inhibitors of CYP3A (e.g., ketoconazole, clarithromycin, nelfinavir) Taking inducers of CYP3A (e.g., phenobarbital, rifampicin)Significant hepatic impairment

Drug Precautions ::

Heart rhythm problems (e.g., bradycardia, QT prolongation, ventricular tachycardia), liver problems, certain uncorrected mineral imbalances (low potassium/magnesium levels), severe kidney problems.

Drug Side Effects ::

Cardiac Disorders – bradycardia, palpitationsEar and Labyrinth Disorders – tinnitus, vertigoGastrointestinal Disorders – abdominal pain, dry mouth, vomitingGeneral Disorders and Administrative Site Adverse Events – peripheral edemaRespiratory, Thoracic, and Mediastinal Disorders – dyspneaVascular Disorders – hypotension, orthostatic hypotension

Pregnancy category ::

3

Drug Mode of Action ::  

Antianginal effects not determined, but does not depend on HR or BP reduction; no effect on rate-pressure product at maximal exercise; shown to inhibit cardiac late sodium current (INA) at therapeutic levels

Drug Interactions ::

Increased plasma levels w/ moderate CYP3A4 inhibitors (e.g. diltiazem, fluconazole, erythromycin), P-glycoprotein inhibitors (e.g. verapamil, ciclosporin) and CYP2D6 inhibitors (e.g. paroxetine). May increase plasma digoxin concentrations. May increase risk of rhabdomyolysis w/ simvastatin. May increase plasma concentrations of atorvastatin, other statins (e.g. lovastatin) and CYP3A4 substrates w/ narrow therapeutic range (e.g. tacrolimus, sirolimus, everolimus). May increase plasma exposure of metformin. Increased risk of ventricular arrhythmias w/ other drugs that prolong QT interval (e.g. terfenadine, astemizole, mizolastine). Potentially Fatal: Increased plasma concentrations leading to increased adverse effects w/ CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, HIV protease inhibitors, clarithromycin, telithromycin, nefazodone). Decreased plasma concentration w/ CYP3A4 inducers (e.g. rifampicin, phenytoin, phenobarbital, carbamazepine). Increased risk of QT interval prolongation w/ class 1A (e.g. quinidine) or class III (e.g. dofetilide, sotalol) antiarrhythmics other than amiodarone.